Gallium‐Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects
Ga-labeled probes, have become standard tools for precise diagnosis of prostate cancer, neuroendocrine tumors, and other malignancies, while Ga therapeutic agents act by interfering with DNA metabolism, regulating tumor immunity, and inhibiting angiogenesis. This review summarizes the current research status of Ga-containing agents in tumor diagnosis and therapy, covering imaging/therapeutic mechanisms and clinical applications, and clarifies their advantages and limitations. To promote their clinical translation, future efforts should focus on AI-assisted multimodal imaging, personalized theranostics, intelligent targeted delivery systems and standardized multicenter clinical promotion.
Authors
- Qi Li (ORCID: https://orcid.org/0000-0001-8776-8730)
- Y Zhou (ORCID: https://orcid.org/0009-0001-2784-7733)
- Dandan Xia (ORCID: https://orcid.org/0000-0002-5712-1423)
- Yue Han
- Yufeng Zheng (ORCID: https://orcid.org/0000-0002-7402-9979)
Institutions
- Peking University (CN)
- National Clinical Research (US)
- Stomatology Hospital (CN)
Publication Details
- Journal
- Small
- Published
- 2026-05-10
- DOI
- https://doi.org/10.1002/smll.73698
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China